Search results for "Transitional cell"

showing 10 items of 77 documents

Segmental Ureterectomy Versus Radical Nephroureterectomy in Older Patients Treated for Upper Tract Urothelial Carcinoma

2022

Introduction: The world population is ageing and surgical procedures for older patients are associated with higher perioperative morbidity and mortality rates than in younger patients. Segmental ureterectomy (SU) has been proposed as an alternative to radical nephroureterectomy (RNU) for selected upper tract urothelial carcinomas (UTUC), to reduce post-operative morbidity, and preserve renal function. The aim of this study was to compare RNU and SU in terms of post-operative complications, functional outcomes, and overall survival (OS) in older patients treated for UTUC. Materials and methods: Data of patients aged 75 years or older and treated for UTUC were included. The primary outcome wa…

Carcinoma Transitional CellSurvivalUreteral NeoplasmsUrologyAged; Kidney sparing surgery; Postoperative complications; Renal function; Survival; Glomerular Filtration Rate; Humans; Nephrectomy; Nephroureterectomy; Postoperative Complications; Retrospective Studies; Carcinoma Transitional Cell; Ureter; Ureteral Neoplasms; Urinary Bladder NeoplasmsCarcinomaUreteral NeoplasmNephrectomyNephroureterectomyPostoperative complicationPostoperative complicationsOncologyUrinary Bladder NeoplasmsRetrospective StudieHumansTransitional CellUreterAged; Kidney sparing surgery; Postoperative complications; Renal function; SurvivalKidney sparing surgeryRetrospective StudiesAgedRenal functionGlomerular Filtration RateHuman
researchProduct

Time to safely omit bladder cuff removal for low-risk upper tract urothelial carcinoma

2021

Carcinoma Transitional Cellmedicine.medical_specialtyUreteral Neoplasmsbusiness.industryUrologyUrologyNephrectomyText miningUrinary Bladder NeoplasmsUpper tractNephrologyCuffHumansMedicinebusinessUrothelial carcinomaMinerva Urology and Nephrology
researchProduct

Prognostic Significance of Histopathological Grading and Immunoreactivity for p53 and p21/WAF1 in Grade 2 pTa Transitional Cell Carcinoma of …

2001

At present, there are no predictors of tumour behaviour for grade (G) 2 pTa transitional cell carcinomas (TCC) of the bladder. Here we analyse the prognostic relevance of histopathological grading and the immunohistochemical detection of p53 and p21/WAF1.70 patients were newly diagnosed with G2 pTa TCC of the bladder based on transurethral resection specimens. Two pathologists, blinded with respect to the clinical outcome, confirmed the initial grade and subclassified the G2 lesions into G2a and G2b carcinomas based on the degree of nuclear atypia and the number of mitoses. Immunoreactivity for p53 and p21/WAF1 was evaluated semiquantitatively.There were 52 G2a and 18 G2b tumours, mean foll…

Cyclin-Dependent Kinase Inhibitor p21Pathologymedicine.medical_specialtyUrologyHistopathological gradingurologic and male genital diseasesCyclinsotorhinolaryngologic diseasesHumansMedicineGrading (tumors)Neoplasm StagingCarcinoma Transitional CellUrinary bladderbusiness.industryPrognosismedicine.diseasefemale genital diseases and pregnancy complicationsP21 waf1medicine.anatomical_structureTransitional cell carcinomaUrinary Bladder NeoplasmsTransitional CellImmunohistochemistryNeoplasm stagingTumor Suppressor Protein p53businessEuropean Urology
researchProduct

Prognostic Value of p53, p21/WAF1, Bcl-2, Bax, Bak and Ki-67 Immunoreactivity in pT1 G3 Urothelial Bladder Carcinomas

2001

pT1 G3 bladder carcinomas are heterogeneous with respect to tumor recurrence and progression. Whereas some urologists treat these carcinomas by repeated transurethral resections often followed by intravesical chemotherapy or BCG instillation, others recommend cystectomy after tumor recurrence or early cystectomy after the initial diagnosis. Our goal was to determine the prognostic value of p53, p21/WAF1, Bcl-2, Bax, Bak, and Ki-67 immunoreactivity in these tumors. There were 30 patients with a new histopathological diagnosis of pT1 G3 urothelial carcinoma based on a transurethral resection specimen. Representative sections of these specimens were examined for the above markers. All patients…

Cyclin-Dependent Kinase Inhibitor p21medicine.medical_specialtyPathologyTime FactorsTumor suppressor genemedicine.medical_treatmentBcl 2 baxUrologyDisease-Free SurvivalCystectomyPredictive Value of TestsCyclinsProto-Oncogene ProteinsBiomarkers TumormedicineHumansNeoplasm InvasivenessRetrospective Studiesbcl-2-Associated X ProteinCarcinoma Transitional CellUrinary bladderBladder cancerbiologyMembrane ProteinsGeneral MedicinePrognosismedicine.diseaseImmunohistochemistrySurvival RateKi-67 Antigenbcl-2 Homologous Antagonist-Killer Proteinmedicine.anatomical_structureTransitional cell carcinomaProto-Oncogene Proteins c-bcl-2Urinary Bladder NeoplasmsTumor progressionKi-67biology.proteinTumor Suppressor Protein p53Follow-Up StudiesTumor Biology
researchProduct

Risk factors for residual disease at re-TUR in a large cohort of T1G3 patients

2021

Item does not contain fulltext Introduction and objectives: The goals of transurethral resection of a bladder tumor (TUR) are to completely resect the lesions and to make a correct diagnosis in order to adequately stage the patient. It is well known that the presence of detrusor muscle in the specimen is a prerequisite to minimize the risk of under staging. Persistent disease after resection of bladder tumors is not uncommon and is the reason why the European Guidelines recommended a re-TUR for all T1 tumors. It was recently published that when there is muscle in the specimen, re-TUR does not influence progression or cancer specific survival. We present here the patient and tumor factors th…

Detrusor musclemedicine.medical_specialty030232 urology & nephrologyUrologyDiseaseLogistic regression03 medical and health sciencesTumor Status0302 clinical medicineRe-transurethral resection of the bladderRecurrenceRisk FactorsUrological cancers Radboud Institute for Molecular Life Sciences [Radboudumc 15]MedicineHumansStage (cooking)Non-muscle invasive bladder cancer; Re-transurethral resection of the bladder; Residual disease; Recurrence; ProgressionNeoplasm StagingRetrospective StudiesUnivariate analysisCarcinoma Transitional CellProgressionbusiness.industryRetrospective cohort studyGeneral MedicineResidual diseaseReconstructive and regenerative medicine Radboud Institute for Health Sciences [Radboudumc 10]Settore MED/24medicine.anatomical_structureUrinary Bladder NeoplasmsConcomitantNon-muscle invasive bladder cancerbusiness
researchProduct

The histology of ovarian cancer: worldwide distribution and implications for international survival comparisons (CONCORD-2).

2016

OBJECTIVE: Ovarian cancers comprise several histologically distinct tumour groups with widely different prognosis. We aimed to describe the worldwide distribution of ovarian cancer histology and to understand what role this may play in international variation in survival. METHODS: The CONCORD programme is the largest population-based study of global trends in cancer survival. Data on 681,759 women diagnosed during 1995-2009 with cancer of the ovary, fallopian tube, peritoneum and retroperitonum in 51 countries were included. We categorised ovarian tumours into six histological groups, and explored the worldwide distribution of histology. RESULTS: During 2005-2009, type II epithelial tumours…

Epidemiology; Histology; Morphology; Ovarain cancer; Worldwide0301 basic medicineOncologyPathologyendocrine system diseasesEpidemiologySex Cord-Gonadal Stromal TumorsCarcinoma Ovarian Epithelial0302 clinical medicineNeoplasmsEpidemiologyNeoplasms Glandular and EpithelialOvarian Neoplasmseducation.field_of_studyEpidemiology; Histology; Morphology; Ovarain cancer; Worldwide; Adolescent; Adult; Aged; Female; Humans; Middle Aged; Neoplasms Germ Cell and Embryonal; Neoplasms Glandular and Epithelial; Ovarian Neoplasms; Sex Cord-Gonadal Stromal Tumors; Oncology; Obstetrics and GynecologyGlandular and EpithelialObstetrics and GynecologyMiddle AgedNeoplasms Germ Cell and Embryonalfemale genital diseases and pregnancy complicationsTransitional cell carcinomaOncology030220 oncology & carcinogenesisClear cell carcinomaFemaleWorldwideHumanMorphologyAdultendocrine systemmedicine.medical_specialtyHistologyAdolescentEpidemiology ; Histology ; Morphology ; Ovarain cancer ; WorldwidePopulationSocio-culturale03 medical and health sciencesInternal medicinemedicineHumansSex Cord-Gonadal Stromal TumorseducationAgedMixed tumorbusiness.industryOvarian NeoplasmSex Cord-Gonadal Stromal TumorHistologymedicine.diseaseOvarain cancerEpidemiology; Histology; Morphology; Ovarain cancer; Worldwide;030104 developmental biologyGerm Cell and EmbryonalOvarian cancerbusinessGynecologic oncology
researchProduct

LOCAL MICROWAVE HYPERTHERMIA AND INTRAVESICAL CHEMOTHERAPY AS BLADDER SPARING TREATMENT FOR SELECT MULTIFOCAL AND UNRESECTABLE SUPERFICIAL BLADDER TU…

1998

Purpose: The role of a combined regimen of local hyperthermia and topical chemotherapy in patients with multifocal and recurrent superficial bladder tumors not curable by transurethral resection was evaluated in a neodjuvant organ sparing clinical study. Materials and Methods: A total of 19 patients with multifocal, superficial grades 1 to 3 bladder tumors that recurred after intravesical chemoprophylaxis or immunoprophylaxis underwent local combined administration of microwave induced hyperthermia and intravesical chemotherapy as a debulking approach. Due to extensive superficial involvement of the bladder walls complete transurethral resection of all tumors seemed technically unfeasible i…

HyperthermiaAdultMalemedicine.medical_specialtymedicine.medical_treatmentUrologyAntineoplastic AgentsCystectomyBladder NeoplasmmedicineHumansMicrowavesAgedAged 80 and overChemotherapyCarcinoma Transitional CellUrinary bladderbusiness.industryintravesical chemotherapy bladder cancer microwave hyperthermiaHyperthermia InducedMiddle Agedmedicine.diseaseDebulkingSurgeryRegimenmedicine.anatomical_structureAdministration IntravesicalUrinary Bladder NeoplasmsChemoprophylaxisFeasibility StudiesFemaleNeoplasm Recurrence LocalbusinessThe Journal of Urology
researchProduct

Podoplanin serum and urine concentration in transitional bladder cancer

2016

Background Podoplanin (PDP) is a mucin - a type of transmembrane protein expressed in numerous tissues during ontogeny and in adult animals, including the brain, heart, kidney, osteoblasts and lymphoid organs. Objective The aim of this study was to determine podoplanin concentration in the blood serum and urine of patients with bladder cancer. Quantifying podoplanin concentration and its correlation with various clinicopathological parameters may be useful for more accurate predictions and identifying high-risk patients. Methods The present study included 82 patients with bladder cancer confirmed by transurethral resection or cystectomy and 27 healthy volunteers. The Surface Plasmon Resonan…

Male0301 basic medicineCancer ResearchPathologymedicine.medical_specialtymedicine.medical_treatmentUrineCystectomy03 medical and health scienceschemistry.chemical_compound0302 clinical medicineBlood serumBiomarkers TumorGeneticsmedicineHumansAgedNeoplasm StagingCarcinoma Transitional CellKidneyCreatinineMembrane GlycoproteinsBladder cancerbusiness.industryGeneral MedicineMiddle AgedSurface Plasmon Resonancemedicine.disease030104 developmental biologymedicine.anatomical_structureTransitional cell carcinomaUrinary Bladder NeoplasmsOncologyPodoplaninchemistryCreatinine030220 oncology & carcinogenesisFemalebusinessCancer Biomarkers
researchProduct

Gemcitabine in intravesical treatment of Ta-T1 transitional cell carcinoma of the bladder: Phase I-II study on marker lesions

2004

Abstract Objectives To study the ablative activity of intravesical gemcitabine against superficial transitional cell carcinoma of the bladder at different doses and concentrations. Methods A total of 27 patients were treated with intravesical gemcitabine after transurethral resection during which one to three papillary marker lesions were left unresected. Starting 14 days after transurethral resection, six instillations of gemcitabine were given at weekly intervals. Gemcitabine, diluted in 50 mL of saline solution and maintained for 2 hours, was given at the dose of 500 mg, 1000 mg, and 2000 mg in groups of 9 patients each. A complete response (CR) was defined as negative cytology, cystosco…

MaleAntimetabolites Antineoplasticmedicine.medical_specialtyUrologyUrinary systemUrologySalvage therapyDeoxycytidineDisease-Free SurvivalSettore MED/24 - UrologiamedicineCarcinomaHumansProdrugsAgedSalvage TherapyCarcinoma Transitional CellUrinary bladderDose-Response Relationship Drugmedicine.diagnostic_testbusiness.industryRemission InductionCystoscopyMiddle Agedmedicine.diseaseGemcitabineGemcitabineGemcitabineSurgeryAdministration IntravesicalTreatment Outcomemedicine.anatomical_structureTransitional cell carcinomaUrinary Bladder NeoplasmsTolerabilityFemaleNeoplasm Recurrence LocalbusinessFollow-Up Studiesmedicine.drug
researchProduct

The Immune Checkpoint Molecule CD200 Is Associated with Tumor Grading and Metastasis in Bladder Cancer.

2018

BACKGROUND We examined the expression of CD200, a ligand of immune tolerance, in transitional cell carcinoma of the human bladder (TCC). MATERIALS AND METHODS CD200 was analyzed by immunohistochemistry (IHC) in 90 patients with suspected TCC lesions of the bladder. Expression of CD200 was exemplarily validated by quantitative reverse transcription polymerase chain reaction and western blot analysis. RESULTS CD200 was detectable at mRNA and protein levels in TCC homogenate and TCC cell lines (T24, UMUC3). TCC tissues showed significantly higher CD200 expression (p<0.005) than normal bladder tissues. CD200 signals were also higher in metastasized compared to localized TCC (p<0.05). CD200 was …

MaleCancer Researchmedicine.medical_treatmenturologic and male genital diseasesMetastasis03 medical and health sciences0302 clinical medicineWestern blotAntigens CDmedicineBiomarkers TumorHumansRNA MessengerRNA NeoplasmNeoplasm MetastasisneoplasmsAgedNeoplasm StagingAged 80 and overCarcinoma Transitional CellBladder cancermedicine.diagnostic_testbusiness.industryCell DifferentiationGeneral MedicineImmunotherapymedicine.diseasefemale genital diseases and pregnancy complicationsImmune checkpointNeoplasm ProteinsReverse transcription polymerase chain reactionTransitional cell carcinomaOncologyUrinary Bladder Neoplasms030220 oncology & carcinogenesisCancer researchImmunohistochemistryFemaleTumor EscapeNeoplasm Gradingbusiness030215 immunologyAnticancer research
researchProduct